The R&D segment will mount a unique and compelling effort in Oncology, Immunology and Regenerative Medicine. iBRAIN will provide a top class RNAi technology based Drug Discovery, Drug Validation and Testing. RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence and regulate such genes selectively through RNAi could provide a means to treat a wide range of human diseases. We promise to offer expertise and experience that enable more efficient product development while maintaining unparallel quality. This will position iBRAIN LifeSciences at the forefront of the new wave of biotech companies in this age of nanotechnology.
The CRO division will provide wide range of Pre Clinical research in our own world class CPCSEA approved animal house facility. We provide Clinical Trial services (Phase I-IV) with our wide net work of hospitals Nation wide. We have an excellent Clinical Data Management (CDM) center at our corporate office. We also provide Bioavailability (BA) and Bioequivalence (BE) projects; will also offer cutting edge nanotechnologies like RNAi and bacteriophages to use in projects like drug discovery and validation and testing.
Finally, the Health Care Provider division will build healthcare facilities in strategic locations around the world to bring quality and affordable healthcare to the regions where affordable healthcare is essential, with particular emphasis on the enormous number of Baby-boomers that are scheduled to start retiring in 2010.